GSK 3862995B
Alternative Names: GSK-3862995BLatest Information Update: 12 Jan 2024
At a glance
- Originator GSK
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Chronic obstructive pulmonary disease
Most Recent Events
- 04 Dec 2023 Preclinical trials in Chronic obstructive pulmonary disease in United Kingdom (unspecified route)
- 27 Nov 2023 Phase-I clinical trials in Chronic obstructive pulmonary disease in United Kingdom (unspecified route) (NCT06154837)
- 27 Nov 2023 GSK plans a phase I trial for Chronic obstructive pulmonary disease in United Kingdom (NCT06154837)